Impact	O
of	O
tumor	B-Cell
cell	I-Cell
VEGF	O
expression	O
on	O
the	O
in	O
vivo	O
efficacy	O
of	O
vandetanib	O
(	O
ZACTIMA	O
;	O
ZD6474	O
)	O
.	O

VEGF	O
is	O
the	O
key	O
player	O
in	O
tumor	B-Cancer
angiogenesis	O
.	O

In	O
the	O
current	O
study	O
,	O
the	O
impact	O
of	O
VEGF	O
expression	O
on	O
the	O
response	O
of	O
tumors	B-Cancer
to	O
the	O
VEGFR2	O
associated	O
tyrosine	O
kinase	O
inhibitor	O
vandetanib	O
was	O
evaluated	O
.	O

MATERIALS	O
AND	O
METHODS	O
:	O
Human	O
colon	B-Cell
carcinoma	I-Cell
(	I-Cell
HT29	I-Cell
)	I-Cell
and	O
murine	O
squamous	B-Cell
carcinoma	I-Cell
(	I-Cell
SCCVII	I-Cell
)	I-Cell
clonal	I-Cell
cell	I-Cell
lines	I-Cell
expressing	O
varying	O
levels	O
of	O
VEGF	O
were	O
established	O
and	O
their	O
response	O
to	O
vandetanib	O
was	O
assessed	O
in	O
tissue	B-Tissue
culture	O
and	O
as	O
solid	B-Cancer
tumors	I-Cancer
.	O

RESULTS	O
:	O
Vandetanib	O
treatment	O
had	O
no	O
effect	O
on	O
tumor	B-Cell
cell	I-Cell
clonogenic	O
cell	B-Cell
survival	O
in	O
vitro	O
but	O
doses	O
>	O
or	O
=	O
10	O
nM	O
significantly	O
reduced	O
endothelial	B-Cell
cell	I-Cell
migration	O
.	O

In	O
vivo	O
,	O
tumors	B-Cancer
derived	O
from	O
cell	B-Cell
clones	I-Cell
expressing	O
high	O
levels	O
of	O
VEGF	O
displayed	O
significantly	O
enhanced	O
angiogenesis	O
and	O
more	O
aggressive	O
growth	O
.	O

An	O
intradermal	B-Immaterial_anatomical_entity
angiogenesis	O
assay	O
was	O
used	O
to	O
demonstrate	O
that	O
a	O
4	O
-	O
day	O
treatment	O
with	O
vandetanib	O
(	O
50	O
mg	O
/	O
kg	O
/	O
day	O
)	O
was	O
able	O
to	O
significantly	O
inhibit	O
blood	B-Multi-tissue_structure
vessel	I-Multi-tissue_structure
growth	O
induced	O
by	O
both	O
parental	O
and	O
high	O
VEGF	O
-	O
expressing	O
tumor	B-Cell
cell	I-Cell
clones	I-Cell
.	O

In	O
the	O
HT29	B-Cancer
tumor	I-Cancer
model	O
,	O
treatment	O
response	O
to	O
vandetanib	O
(	O
50	O
mg	O
/	O
kg	O
/	O
day	O
,	O
Monday	O
-	O
Friday	O
for	O
2	O
weeks	O
)	O
was	O
greatest	O
in	O
xenografts	B-Cancer
derived	O
from	O
the	O
highest	O
VEGF	O
-	O
expressing	O
cell	B-Cell
clones	I-Cell
.	O

A	O
similar	O
trend	O
was	O
noted	O
in	O
the	O
SCCVII	B-Cancer
tumor	I-Cancer
model	O
.	O

The	O
present	O
findings	O
indicate	O
that	O
vandetanib	O
therapy	O
effectively	O
counteracted	O
the	O
aggressive	O
feature	O
of	O
tumor	B-Cancer
growth	O
resulting	O
from	O
VEGF	O
over	O
-	O
expressing	O
tumor	B-Cell
cells	I-Cell
and	O
suggest	O
that	O
such	O
tumors	B-Cancer
may	O
be	O
particularly	O
well	O
suited	O
for	O
anti	O
-	O
VEGF	O
interventions	O
.	O

